Israel - hebreiska - Ministry of Health

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Israel - hebreiska - Ministry of Health

novartis israel ltd - brinzolamide; timolol as maleate - תרחיף לעין - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Israel - hebreiska - Ministry of Health

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated.

Israel - hebreiska - Ministry of Health

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated..

Israel - hebreiska - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - קפסולות - duloxetine as hydrochloride 60 mg - duloxetine

Israel - hebreiska - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - קפסולות - duloxetine as hydrochloride 30 mg - duloxetine

Israel - hebreiska - Ministry of Health

padagis israel agencies ltd, israel - bifonazole; urea - משחה - urea 40 %; bifonazole 1 % - bifonazole - bifonazole - for nail stripping and antifungal treatment of fungal infections of the finger nails and toe nails.

Israel - hebreiska - Ministry of Health

perrigo israel pharmaceuticals ltd - bifonazole; urea - משחה - bifonazole 1 %; urea 40 % - imidazole and triazole derivatives - for nail stripping and antifungal treatment of fungal infections of the finger nails and toe nails.

Israel - hebreiska - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Israel - hebreiska - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.